Cannabis and Anxiety: a Biopsychosocial Model
Purpose of Review
The current paper presents a biopsychosocial model of cannabis use and anxiety that focuses explicitly on aspects of anxiety that may contribute to cannabis use and use-related problems among individuals with elevated anxiety.
Elevated anxiety and anxiety disorders are common among individuals who use cannabis and those with cannabis use disorder (CUD). One possible explanation for this co-occurrence may be that symptoms associated with anxiety disorders (i.e., physiological arousal, subjective anxiety, and avoidance) may place anxious individuals at risk of using cannabis to cope with these symptoms.
A review of the literature on the relationships between facets of anxiety and cannabis use and related problems partially supports the utility of this model and informs future directions for research and treatment in this area.
KeywordsCannabis Marijuana Anxiety Anxiety disorders Biopsychosocial Review
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2018.Google Scholar
- 2.Center for Behavioral Health Statistics and Quality. 2017 National survey on drug use and health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration 2018.Google Scholar
- 11.Flórez-Salamanca L, Secades-Villa R, Budney AJ, García-Rodríguez O, Wang S, Blanco C. Probability and predictors of cannabis use disorders relapse: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2013;132(1):127–33. https://doi.org/10.1016/j.drugalcdep.2013.01.013.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry. 2016;173(6):588–99. https://doi.org/10.1176/appi.ajp.2015.15070907.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Buckner JD, Heimberg RG, Schneier FR, Liu S-M, Wang S, Blanco C. The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2012;124(1-2):128–34. https://doi.org/10.1016/j.drugalcdep.2011.12.023.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Soc Psychiatry Psychiatr Epidemiol. 2001;36(5):219–27. https://doi.org/10.1007/s001270170052.CrossRefPubMedGoogle Scholar
- 19.• Hill S, Shanahan L, Costello EJ, Copeland W. Predicting persistent, limited, and delayed problematic cannabis use in early adulthood: findings from a longitudinal study. J Am Acad Child Adolesc Psychiatry. 2017;56(11):966–74. https://doi.org/10.1016/j.jaac.2017.08.012 This study demonstrates that adolescents whose problematic cannabis use behaviors (i.e., cannabis use disorder or daily use) persist into adulthood are more likely to have been diagnosed with an anxiety disorder in childhood or adolescence than those with limited problematic cannabis use behaviors. CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Lopez-Quintero C, de los Pérez Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120–30. https://doi.org/10.1016/j.drugalcdep.2010.11.004.CrossRefPubMedGoogle Scholar
- 21.Marel C, Sunderland M, Mills KL, Slade T, Teesson M, Chapman C. Conditional probabilities of substance use disorders and associated risk factors: progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids. Drug Alcohol Depend. 2019;194:136–42. https://doi.org/10.1016/j.drugalcdep.2018.10.010.CrossRefPubMedGoogle Scholar
- 25.Butterworth P, Slade T, Degenhardt L. Factors associated with the timing and onset of cannabis use and cannabis use disorder: results from the 2007 Australian National Survey of Mental Health and Well-Being. Drug and Alcohol Rev. 2014;33(5):555–64. https://doi.org/10.1111/dar.12183.CrossRefGoogle Scholar
- 26.Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ. Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: an analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiatr Res. 2015;66-67:135–41. https://doi.org/10.1016/j.jpsychires.2015.05.004.CrossRefPubMedGoogle Scholar
- 29.Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and anxiety disorders: results from a population-based representative sample. Eur Neuropsychopharmacol : the journal of the European College of Neuropsychopharmacology. 2016;26(3):493–505. https://doi.org/10.1016/j.euroneuro.2015.12.037.CrossRefGoogle Scholar
- 31.Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. 2nd ed. New York: Guilford Press; 2002. p. xvi–704.Google Scholar
- 32.Haring M, Guggenhuber S, Lutz B. Neuronal populations mediating the effects of endocannabinoids on stress and emotionality. Neuroscience. 2012;204:145–58. https://doi.org/10.1016/j.neuroscience.2011.12.035.CrossRefPubMedGoogle Scholar
- 42.Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2004;29(2):417–26. https://doi.org/10.1038/sj.npp.1300340.CrossRefGoogle Scholar
- 43.Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2011;36(6):1219–26. https://doi.org/10.1038/npp.2011.6.CrossRefGoogle Scholar
- 44.Linares I, Zuardi AW, Pereira LCG, Queiroz RHC, Mechoulam R, Guimarães FS, et al. P.4.c.008 - cannabidiol presents an inverted U-shaped dose-response curve in the simulated public speaking test. Eur Neuropsychopharmacol: the journal of the European College of Neuropsychopharmacology. 2016;26:S617. https://doi.org/10.1016/S0924-977X(16)31702-3.CrossRefGoogle Scholar
- 45.•• Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, JEC H, Guimarães FS, et al. Inverted u-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017;8:259. https://doi.org/10.3389/fphar.2017.00259 This CBD administration study compares the effects of CBD on anxiety to clonazepam and placebo using both subjective and physiological measures of anxiety. Results suggest that CBD at moderate (but not low or high) doses reduced subjective (but not physiological) measures of anxiety. CrossRefPubMedPubMedCentralGoogle Scholar
- 51.•• National Academies of Sciences E, Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington: The National Academies Press; 2017. The authors summarized current research regarding cannabis and anxiety, highlighting that there is limited evidence supporting the use of cannabis for the treatment of anxiety disorders. Google Scholar
- 52.Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. Correction to: New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 2019. https://doi.org/10.1007/s00406-019-01020-1.
- 54.Buckner JD, Zvolensky MJ, Ecker AH, Jeffries ER. Cannabis craving in response to laboratory-induced social stress among racially diverse cannabis users: the impact of social anxiety disorder. J Psychopharmacol (Oxford, England). 2016;30(4):363–9. https://doi.org/10.1177/0269881116629115.CrossRefGoogle Scholar
- 59.Johnson KA, Bonn-Miller MO, Leyro TM, Zvolensky MJ. Anxious arousal and anhedonic depression symptoms and the frequency of current marijuana use: testing the mediating role of marijuana-use coping motives among active users. J Stud Alcohol Drugs. 2009;70(4):543–50.CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Buckner JD, Silgado J, Schmidt NB. Marijuana craving during a public speaking challenge: understanding marijuana use vulnerability among women and those with social anxiety disorder. J Behav Ther Exp Psychiatry. 2011;42:104–10. https://doi.org/10.1016/j.jbtep.2010.07.005.CrossRefPubMedGoogle Scholar
- 65.Buckner JD, Zvolensky MJ, Crosby RD, Wonderlich SA, Ecker AH, Richter AA. Antecedents and consequences of cannabis use among racially diverse cannabis users: an analysis from ecological momentary assessment. Drug Alcohol Depend. 2015;147:20–5. https://doi.org/10.1016/j.drugalcdep.2014.12.022.CrossRefPubMedGoogle Scholar
- 69.• Buckner JD, Zvolensky MJ, Ecker AH, Schmidt NB, Lewis EM, Paulus DJ, et al. Integrated cognitive behavioral therapy for comorbid cannabis use and anxiety disorders: a pilot randomized controlled trial. Behav Res Ther. 2019;115:38–45. https://doi.org/10.1016/j.brat.2018.10.014 This is an important treatment study that demonstrates initial support for a novel transdiagnostic treatment designed for individuals with cannabis use disorder and at least one co-occurring anxiety disorder. CrossRefPubMedGoogle Scholar
- 70.Zvolensky MJ, Marshall EC, Johnson K, Hogan J, Bernstein A, Bonn-Miller MO. Relations between anxiety sensitivity, distress tolerance, and fear reactivity to bodily sensations to coping and conformity marijuana use motives among young adult marijuana users. Exp Clin Psychopharmacol. 2009;17(1):31–42. https://doi.org/10.1037/a0014961.CrossRefPubMedPubMedCentralGoogle Scholar
- 72.Fatseas M, Serre F, Swendsen J, Auriacombe M. Effects of anxiety and mood disorders on craving and substance use among patients with substance use disorder: an ecological momentary assessment study. Drug Alcohol Depend. 2018;187:242–8. https://doi.org/10.1016/j.drugalcdep.2018.03.008.CrossRefPubMedGoogle Scholar
- 74.•• Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2016;36(5):511–35. https://doi.org/10.1002/phar.1747 In this important review, the authors review clinical trials for cannabis use disorder (CUD) and suggest that current treatments are only moderately efficacious in reducing cannabis use and even less efficacious for maintaining abstinence. This review highlights the importance of continuing to research and develop novel treatments for CUD. CrossRefGoogle Scholar
- 77.APA Society of Clinical Psychology Division 12. Psychological Treatments. 2019. www.div12.org/treatments. Accessed 14 May 2019.
- 78.Steinberg KL, Roffman RA, Carroll KM, McRee B, Babor T, Miller M et al. Brief counseling for marijuana dependence: a manual for treating adults. Center for Substance Abuse Treatment, Substance Abuse and Mental Health …; 2005.Google Scholar
- 79.Heimberg RG, Becker RE. Cognitive-behavioral group therapy for social phobia: basic mechanisms and clinical strategies. Treatment manuals for practitioners. New York: Guilford Press; 2002.Google Scholar
- 81.Schmidt NB, Buckner JD, Pusser A, Woolaway-Bickel K, Preston JL, Norr A. Randomized controlled trial of false safety behavior elimination therapy: a unified cognitive behavioral treatment for anxiety psychopathology. Behav Ther. 2012;43(3):518–32. https://doi.org/10.1016/j.beth.2012.02.004.CrossRefPubMedGoogle Scholar
- 82.Buckner JD, Zvolensky MJ, Lewis EM. On-line personalized feedback intervention for negative affect and cannabis: a pilot randomized controlled trial. Exp Clin Psychopharmacol. 2019. https://doi.org/10.1037/pha0000304.
- 89.•• Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics. 2015;12(4):825–36. https://doi.org/10.1007/s13311-015-0387-1 This important review discusses evidence for anxiolytic properties of cannabidiol (CBD) from both preclinical animal models and human research studies. Findings highlight CBD as a potential treatment for anxiety and related disorders, with the caveat that much more human subjects research is required to determine its efficacy among clinical populations. CrossRefGoogle Scholar